Keyphrases
Parkinson's Disease
100%
Leucine-rich Repeat Kinase 2 (LRRK2)
81%
Rab10
21%
Idiopathic Parkinson's Disease
20%
Phosphorylation
19%
VPS35
14%
Kinase Cascade
13%
Clinical Trials
13%
R1441C
12%
Disease-modifying Therapy
11%
Peripheral Blood Neutrophils
9%
Dementia with Lewy Bodies
9%
Pathogenicity
9%
Peripheral Blood
9%
Brain Cells
9%
Disease-associated
9%
Lysosome
9%
Human Peripheral Blood
9%
Mitochondrial DNA Damage
8%
Bisphosphonates
8%
Genetic Screening
8%
Early-onset Dementia
8%
Austrian
8%
New Disease
8%
Dementia Patients
8%
Tagless
8%
Clinical Samples
8%
Genetic Testing
8%
Kinase Activity
8%
Mutation Carriers
8%
Parkinson
8%
Patient Stratification
7%
Parkinson Patients
7%
Protein Phosphorylation
6%
McLeod Syndrome
6%
Erythrocytes
6%
Parkinson's Disease Dementia
6%
Pathway Activity
6%
Single-arm Trial
6%
Monogenic
6%
Pathogenic Variants
5%
Molecular Mechanism
5%
LRRK2 Kinase
5%
Neurodegeneration
5%
Penetrance
5%
Targeted Mass Spectrometry
5%
Sortilin-related Receptor
5%
Receptor 1
5%
Gene Targeting
5%
Human Neutrophils
5%
Biochemistry, Genetics and Molecular Biology
Kinase
61%
Phosphotransferase
61%
Leucine-Rich Repeat
54%
LRRK2
33%
Genetics
31%
Clinical Trial
22%
Genetic Screening
17%
VPS35
13%
Mass Spectrometry
9%
Lysosome
9%
Protein Phosphorylation
9%
Penetrance
8%
DNA Damage
8%
Mitochondrial DNA
8%
Immunocompetent Cell
6%
TREM2
5%
Protein Kinases
5%
Transgenic Mouse
5%
